The treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
|
|
- Basil Barton
- 6 years ago
- Views:
Transcription
1 The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
2 NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37% CLL/SLL 15 % MALT lymphoma 7% Follicular Lymphoma 20 %
3 DLBCL: either cured or dead IOSI Database Ghielmini and Zucca, Blood 2009
4 1993: CHOP is the best 100% 80% OVERALL SURVIVAL 60% 40% 20% 0 Regimen pts deaths 3-yr OS Pro-MACE-CytaBOM % MACOP-B % m-bacod % CHOP % P = years Fisher et al, NEJM, 1993
5 Strategies to improve on CHOP 1. Adding more drugs 2. Dose-intensification 3. Myeloablative consolidation 4. Addition of rituximab 5. Adding radiotherapy
6 1.- More drugs improve survival? ACVBP better than CHOP CHOP + Vindesine Bleomycine Ifosfamide Etoposide AraC
7 LNH03-2B study R-ACVBP is superior to R-CHOP R-ACVBP vs R-CHOP, patients <60, aaipi=1 Recher et al., Lancet 2011;378(9806):
8 2.- Shorter intervals improve survival? CHOP 14 >CHOP 21 CHOP-14 vs. CHOP-21 p < Pfreundschuh et al, Blood 2004
9 Dose-dense not better R-CHOP 21 vs R-CHOP 14 if rituximab is added PFS OS Cunningham D et al.lancet 2013;381: Delarue R et al. Lancet Oncol. 2013;14:525-33
10 3.- is HDCT mandatory? Milpied et al, NEJM 2006
11 Meta-analysis of HDCT trials Greb et al., 2007, Cancer Treat Rev
12 Consolidation by HDT and ASCT In the R-era EFS OS Stiff PJ et al. N Engl J Med Vitolo U et al. ICML 2011.
13 4.- Rituximab improves survival Elderly population, Can not be rescued by HDCT at relapse Feugier et al, JCO, 2005
14 Overall survival by treatment era All Patients in British Columbia: N=294 Mixed population, Half could be rescued by HDCT at relapse Sehn, L. H. et al. J Clin Oncol; 2005
15 5.- Can Radiotherapy improve on systemic treatment? Retrospective study of patients with DLBCL reciving chemo +/- consolidation radiotherapy in the R-era in the NCCN centres (n=841) Failure Free Survival Overall Survival P=0.06 P= % had stage I-II 23% had bulky disease 35% of cohort received RT 119 deaths: 88 in CHOP-R and 31 CHOP-R+RT Dabaja at al, Abstr 121, 12-ICML, Lugano 2013
16 Survival curves according to PET positivity and performed RT PROGRESSION-FREE SURVIVAL Positive- XRT (n=60) OVERALL SURVIVAL Positive- XRT (n=60) Percent Survival Negative (n=167) Positive- No XRT (n=22) 2 4 Time (years) 6 8 Percent Survival Negative (n=167) Positive- No XRT (n=22) 4 Time (years) Sehn at al, Abstr 123, 12-ICML, Lugano
17 1st-line treatment guidelines: ESMO 60 years > 60 years IPI low risk, no bulk Low risk with bulk or low intermediate risk R-CHOP21 6 R-ACVBP R-CHOP RT Fit R-CHOP21 6 > 80 years R-miniCHOP21 6 High intermediate or high risk R-CHOP21 8 R-CHOP R or intensify Unfit or cardiac dysfunction Substitute doxorubicin with etoposide, liposomal doxorubicin or others
18 Treatment of relapse: Parma trial HDCT better than standard CT Event-free survival Overall survival Transplantation Conventional chemotherapy EFS (%) OS (%) p = p = Months after randomisation Months after randomisation Philip et al. N Engl J Med 1995;333:1540.
19 Is there a better induction therapy? ICE/R-ICE vs DHAP/R-DHAP Gisselbrecht at al, JCO, 2010 Gisselbrecht et al. J Clin Oncol 2010; 28:4184.
20 Canadian study: GDP vs DHAP (+ R since 2005) EFS OS QoL Crump at al, Abstr 85, 12-ICML, Lugano 2013
21 Auto vs allo -transplant EBMT database, OS Autologous 132 Myeloablative allo 98 RIC allo All as first transplant Robinson et al, BMT 2016
22 Treatment of relapse: ESMO 1st relapse 2nd relapse Eligible for transplant Platinum-based induction If response: HDT + PBSCT Allogeneic transplant Not eligible for transplant Platinum- and/or gemcitabine-based regimens Clinical trials BSC Ghielmini et al. Ann Oncol 2013;24:561. Tilly et al. Ann Oncol 2012;23(Suppl 7):vii78.
23 Risk of secondary CNS relapse: DSHNHL (n=2164) and BCCA (n=1597) 0.40 Risk factors Proportion Median time to CNS relapse - DSHNHL 7.2 months - BCCA 6.7 months Age > 60 LDH > N PS > 1 E > 1 Stage > II Renal or adrenal Number of factors: IPI Years Savage et al, ASH 2014, abstr. 394
24 Older patients are often not treated Retrospective SEER Db: 9333 DLBCL patients > 66 years enrolled Medicare A/B Hamlin P et al, The Oncologist, 2014
25 Overall survival of advanced-stage DLBCL aged > 70 by therapy group S. A. M. van de Schans et al. Ann Oncol 2012;23:
26 TRM and Toxicity is greatest in initial cycles of therapy: prephaseimpact Vincristine 1 mg + Prednisone 100 mg x 7 days in DSHNHL NHL-B2 Trial Therapy associated mortality before and after institution of Pre-Phase NHL-B2 Courtesy M. Pfreundschuh
27 Cardiac comorbidity: gemcytabine or etoposide instead of doxo n=62 Median age 76.5 (52-90) Adv Stage: 69% Case-control study of R-CEOP (n=81) or R-CHOP (n=162) in DLBCL Disease Specific survival IPI 3-5: 71% All with cardiac disease R-CHOP R-CEOP Fields P A et al. JCO 2014;32: Moccia et al, ASH 2000
28 DH lymphomas have a bad prognosis BL DHL DLBCL Snuderl et al, Am J Surg Pathol, 2010
29 Bcl-2 +/ Myc + Gene translocation vs protein expression FISH IHC DHL = 11 DEL = 54 Green et al, JCO, % cases Well reproducible Consistent data 30% cases Not well reproducible Less consistent data
30 High grade B-cell Lymphomas Diagnostic approach MYC+ MYC+ DH+ DH+ DH+ DH+ Swerdlow et al, Blood 2016, in press
31 23 US CCC: retrospective analysis Induction treatment N = 311 previously untreated DHL Intensive = DA-EPOCH, Hyper CVAD, CODOX-M-IVAC PFS OS Petrich et al., Blood, 2014
32 23 US CCC: retrospective analysis Consolidation treatment N = 151/311 DHL in CR Petrich et al., Blood, 2014
33 Meta-analysis of 11 DHL studies N = 394 R-CHOP = 180 R-EPOCH = 91 Dose-intensive = 123 (R-HyperCVAD/R-MC or R-CODOX-M/R-IVAC) Howlett et al., BJH, 2015
34 Conclusions R-CHOP is the standard treatment for DLBCL Different types of intensification might obtain slightly better results, at the cost of higher toxicity For relapsed patients, HDT is the only curative option For DH lymphomas the best treatment is unknown: inducing with DA-R-EPOCH and consolidating with HDCT is a possible option Try to treat elderly in a curative manner Dont forget the risk of CNS relapse
Radiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationTraitement des lymphomes diffus à grandes cellules B
Traitement des lymphomes diffus à grandes cellules B Corinne HAIOUN Unité Hémopathies Lymphoïdes- CHU Henri Mondor Université Paris Est Créteil DES Hématologie Février 2012 On February 10th, the merging
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationLYMPHOMA in HIV PATIENTS. Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma
LYMPHOMA in HIV PATIENTS Silvia Montoto, St Bartholomew s Hospital, London, UK ESMO Preceptorship on Lymphoma Lugano, 3-4 November 2017 Disclosures: Roche: honoraria Gilead: travel grant ESMO Preceptorship
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationPost-ESMO Berne
Post-ESMO Berne 23.10.2015 Lymphoma Update Panagiotis Samaras Department of Oncology Hemato-Oncology Center University Hospital Zurich Diffuse Large B-Cell Lymphoma (DLBCL) PCNSL Hodgkin s Lymphoma Mantle
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationMODERN MANAGEMENT OF DLBCL. Ruth Pettengell St George s University of London
MODERN MANAGEMENT OF DLBCL Ruth Pettengell St George s University of London NHL OVERVIEW B T NHL 85% 15% Main B-cell lymphomas distribution DLBCL: The commonest subtype MALT 9% Follicular 29% Lymphoma
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationTransformed lymphoma: biology and treatment
Transformed lymphoma: biology and treatment Silvia Montoto Centre for Haemato-Oncology Barts Cancer Institute 1.00 0.75 0.50 0.25 0.00 N =330 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Years %Viability
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationTreatment Strategies for Double Hit/Double Protein Lymphoma. Adam M. Petrich, MD Northwestern University
Treatment Strategies for Double Hit/Double Protein Lymphoma Adam M. Petrich, MD Northwestern University October 24, 2015 Courtesy: Kieron Dunleavy, MD Double-protein lymphomas (DPL) DPL=double protein
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationFollicular Lymphoma. Michele Ghielmini. Oncology Institute of Southern Switzerland Bellinzona
Follicular Lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Astra Zeneca Roche Cellgene Mundipharma Janssen Gilead Bayer Abbvie FL remains an incurable
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationToday, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center
Today, how many PTCL patients are cured? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Today, how many PTCL patients are cured? Some but not as many
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationHSCT in Burkitt Lymphoma
HSCT in Burkitt Lymphoma Syed Osman Ahmed KFSHRC, Riyadh Saudi Arabia 3 rd WBMT Scientific Symposium Cape Town 16 Nov 2014 Burkitt Lymphoma: A story of many stories Denis Burkitt 1958 Infection and Cancer
More informationREVIEW. KEY WORDS: Diffuse large B cell lymphoma, Hematopoietic stem cell transplantation, Systematic evidencebased review, Therapy, Adult
REVIEW The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review Denise M. Oliansky, 1 Myron
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationDouble hit lymphoma Clinical perspectives
Double hit lymphoma Clinical perspectives Peter Johnson Some definitions, for clarity Double-hit lymphoma (5% of DLBL) Rearranged MYC (8q24) by FISH Plus either rearranged BCL2 (18q21) or BCL6 (3q27) Double-expression
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationRelapsed/Refractory Diffuse Large B-Cell Lymphoma John Kuruvilla, MD Princess Margaret Cancer Centre University of Toronto
Relapsed/Refractory Diffuse Large B-Cell Lymphoma John Kuruvilla, MD Princess Margaret Cancer Centre University of Toronto Disclosures Research Support Employee Leukemia and Lymphoma Society US, Rasch
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationT-cell Lymphomas Biology and Management
T-cell Lymphomas Biology and Management March-27-2017 Outline Epidemiology Initial Work-up International Prognostic Index Treatment of Diffuse Large B-cell Lymphoma: -Limited Stage -Advanced Stage Frontline:
More informationShould peripheral T-cell lymphoma be treated by autologous or allogeneic SCT?
Francesco d Amore, MD, PhD Dept. Of Hematology Aarhus University Hospital, Aarhus, Denmark Should peripheral T-cell lymphoma be treated by autologous or allogeneic SCT? Disclosure of Interest: Nothing
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationPeripheral T-Cell Lymphoma. Pro auto. Peter Reimer. Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation
Peripheral T-Cell Lymphoma Pro auto Peter Reimer Klinik für Hämatologie / intern. Onkologie und Stammzelltransplantation Kliniken Essen Süd, Evang. Krankenhaus Essen-Werden ggmbh COSTEM, Berlin 09.09.2011
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationHow I treat High-risk follicular lymphoma
How I treat High-risk follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona 1) median OS raised from 10 to 18 y 2) advanced FL remains uncurable Stanford, n = 1334
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationOutcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions
Outcome of DLBCL patients over 80 years: A retrospective survey from 4 Institutions AA Moccia, S Gobba, A Conconi, S Diem, L Cascione, K Aprile von Hohenstaufen, W Gulden Sala, A Stathis, F Hitz, G Pinotti,
More informationNon-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection. Arnold Freedman, M.D.
2017 Master Class for Oncologists Non-Hodgkin s and Hodgkin lymphoma: using disease characteristics as a guide to treatment selection Arnold Freedman, M.D. 2018 Master Class Course Disclosure Disclosure
More informationThe Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma
The Role of Stem Cell Transplantation in Relapsed / Refractory Hodgkin s Lymphoma Anna Sureda Haematology Department Institut Catala d Oncologia Hospital Duran I Reynals Barcelona, Spain 10 th Educational
More informationASCO abstract June 2007 :Othieno-Abinya NA, Abwao HO, Kiarie GW)
Inferior outcome of poor prognostic phenotype non- Hodgkin s lymphoma treatment among HIV positive patients compared with HIV negative counterparts in the HAART era. (ASCO abstract June 2007 :Othieno-Abinya
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationJOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
More informationBLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION
BLOOD RESEARCH VOLUME 50 ㆍ NUMBER 3 September 2015 ORIGINAL ARTICLE Prediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationSimposio COSA È CAMBIATO NELL APPROCCIO TERAPEUTICO DEI LINFOMI NON HODGKIN DEL PAZIENTE ANZIANO?
58 Congresso Nazionale Società Italiana di Gerontologia e Geriatria Torino 27-30 novembre 2013 Simposio COSA È CAMBIATO NELL APPROCCIO TERAPEUTICO DEI LINFOMI NON HODGKIN DEL PAZIENTE ANZIANO? C è un ruolo
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx128 Published online 7 April 2017
Annals of Oncology 28: 54 546, 27 doi:.93/annonc/mdx28 Published online 7 April 27 ORIGINAL ARTICLE Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the
More informationLymphoma Update 2018
Lymphoma Update 2018 Sonali M. Smith, MD Elwood V. Jensen Professor of Medicine Section of Hematology/Oncology Director, Lymphoma Program The University of Chicago April 18, 2018 Disclosure Information
More informationLINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES.
Congreso Nacional SEAP 2013. LINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES. Santiago Montes Moreno Servicio de Anatomía Patológica, HUMV
More informationLinfoma de Hodgkin. Novos medicamentos. Otavio Baiocchi CRM-SP
Linfoma de Hodgkin Novos medicamentos Otavio Baiocchi CRM-SP 96.074 Hodgkin Lymphoma Unique B-cell lymphoma HRS malignant cells Scattered malignant Hodgkin-Reed-Sternberg (RS) cells in a background of
More informationLearn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1
Learn more about diffuse large B-cell lymphoma (DLBCL), the most common aggressive form of B-cell non-hodgkin s lymphoma 1 Expression of B-cell surface antigens drives several non-hodgkin s lymphomas (NHLs)
More informationTrial Registration: # NCT Sponsors & Collaborators: Supported by research funding from Amgen, Inc.
Phase 2 Study of the Bispecific T-cell Engager (BiTE) Antibody Blinatumomab in relapsed/refractory Diffuse Large B-cell Lymphoma Viardot, A, Goebeler, ME, Hess G et al., Blood 2016; 127(11): 1410-1416.
More informationPeripheral T-cell lymphoma. Matt Ahearne Clinical Lecturer, Leicester
Peripheral T-cell lymphoma Matt Ahearne Clinical Lecturer, Leicester PTCL Objectives To understand the natural history of PTCL To appreciate the importance of accurate diagnosis of PTCL including recent
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationModified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo
More informationExpanding the Horizons )N 3UPPORTIVE #ARE /NCOLOGY. Communiqué from ICML 2008
C A n a d i a n V i s i o n f o r O n c o l o g y )N 3UPPORTIVE #ARE /NCOLOGY Number 10 July 2008 PUBLICATIONS MAIL AGREEMENT NO. 41495516 RETURN UNDELIVERABLE CANADIAN ADDRESSES TO NEW EVIDENCE 4133 DUNDAS
More informationACCME/Disclosures. DLBCL, NOS from the clinician perspective. Diffuse large B cell lymphoma
, NOS from the clinician perspective John P. Leonard, M.D. Weill Cornell Medicine New York Presbyterian Hospital ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationONCOLOGY LETTERS 14: , 2017
ONCOLOGY LETTERS 14: 3803-3808, 2017 Upfront high dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high risk diffuse large B cell lymphoma
More informationTreating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma
Treating Frail Adults With Common Malignancies: Best Evidence to Personalize Therapy Treating for Cure or Palliation: Difficult Decisions for Older Adults with Lymphoma Raul Cordoba, MD, PhD Lymphoma Unit
More informationClinical Controversies of Double-Hit Lymphoma
Clinical Controversies of Double-Hit Lymphoma Deborah M. Stephens, DO, and John W. Sweetenham, MD Abstract Double-hit lymphoma (DHL) has been identified as a subset of diffuse large B-cell lymphoma with
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationAggressive B-cell lymphomas and gene expression profiling towards individualized therapy?
Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy? Andreas Rosenwald Institute of Pathology, University of Würzburg, Germany Barcelona, June 18, 2010 NEW WHO CLASSIFICATION
More information